Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 79Neoplasms 9Carcinoma, Intraductal, Noninfiltrating 5Breast Neoplasms, Male 4Neoplasm Metastasis 3Breast Carcinoma In Situ 3Arthralgia 3Triple Negative Breast Neoplasms 2Sexual Dysfunction, Physiological 1Seizures 1Recurrence 1Pain 1Osteoporosis 1Obesity 1Multiple Endocrine Neoplasia Type 1 1Lethal Congenital Contracture Syndrome 2 1Joint Diseases 1Invasive Breast Cancer 1Hypogonadism 1Granulosa Cell Ovarian Cancer 1Fractures, Bone 1Erectile Dysfunction 1Epilepsy 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Metastatic 1Advanced Metastatic Breast Cancer 1Advanced Breast Carcinoma 1

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Breast Carcinoma × Anastrozole × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡